New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 11, 2012
10:21 EDTAU, SWN, RRC, QEP, LIFE, IPI, IPCI, HMY, GFI, COG, BMY, YELPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AngloGold (AU) initiated with an Outperform at Credit Suisse... Bristol-Myers (BMY) reinstated with a Neutral at Credit Suisse... Cabot Oil & Gas (COG) initiated with an Outperform at Bernstein... Gold Fields (GFI) initiated with a Neutral at Credit Suisse... Harmony Gold (HMY) initiated with an Underperform at Credit Suisse... Intellipharmaceutics (IPCI) initiated with a Buy at Brean Murray... Intrepid Potash (IPI) initiated with a Buy at Wunderlich... Life Technologies (LIFE) initiated with a Buy at WallachBeth... QEP Resources (QEP) initiated with an Outperform at BMO Capital... Range Resources (RRC) initiated with an Outperform at Bernstein... Southwestern Energy (SWN) initiated with an Outperform at Bernstein... Yelp (YELP) initiated with a Neutral at Piper Jaffray.
News For AU;BMY;COG;GFI;HMY;IPCI;IPI;LIFE;QEP;RRC;SWN;YELP From The Last 14 Days
Check below for free stories on AU;BMY;COG;GFI;HMY;IPCI;IPI;LIFE;QEP;RRC;SWN;YELP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 2, 2014
07:12 EDTBMYCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
07:10 EDTBMYAlder Biopharmaceuticals regains worldwide rights to clazakizumab
Subscribe for More Information
06:07 EDTCOGCabot Oil & Gas upgraded to Buy from Hold at Stifel
Subscribe for More Information
August 31, 2014
13:31 EDTQEPHart Energy to hold a conference
Subscribe for More Information
12:50 EDTBMYEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
11:15 EDTIPIIntrepid Potash management to meet with Piper Jaffray
Meeting to be held on Los Angeles on September 4 hosted by Piper Jaffray.
August 28, 2014
16:47 EDTIPCIIntellipharmaceutics announces overdose deterrence technology
Subscribe for More Information
August 27, 2014
09:53 EDTBMYOn The Fly: Analyst Initiation Summary
Bristol-Myers (BMY) initiated with a Hold at Deutsche Bank... ASML (ASML) initiated with a Hold at Stifel... Akamai (AKAM) initiated with an Outperform at RW Baird... Concur (CNQR) initiated with a Neutral at DA Davidson... CyrusOne (CONE) initiated with a Neutral at Citigroup... Eli Lilly (LLY) initiated with a Buy at Deutsche Bank... Garmin (GRMN) initiated with a Neutral at RW Baird... Merck (MRK) initiated with a Hold at Deutsche Bank... NetSuite (N) initiated with a Buy at DA Davidson... Oracle (ORCL) initiated with a Neutral at DA Davidson... Oxford Industries (OXM) initiated with a Buy at Wunderlich... Pfizer (PFE) initiated with a Buy at Deutsche Bank... ServiceNow (NOW) initiated with a Buy at DA Davidson... Workday (WDAY) initiated with a Neutral at DA Davidson... MannKind (MNKD) initiated with a Buy at Jefferies... STMicroelectronics (STM) initiated with an Underperform at Credit Suisse... Kirkland's (KIRK) initiated with an Outperform at Barrington.
06:42 EDTBMYBristol-Myers initiated with a Hold at Deutsche Bank
Target $52.
05:44 EDTBMYBristol-Myers Daklinza approved by EC
Bristol-Myers announced that the European Commission, or EC, has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus, or HCV, infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the European Union and will be available for use in combination with other medicinal products, providing a shorter treatment duration compared to 48 weeks of treatment with interferon- and ribavirin-based regimens. The approval allows for the marketing of Daklinza in all 28 Member States of the EU. The marketing authorization for Daklinza follows an accelerated assessment by the Committee for Medicinal Products for Human Use, a designation that is granted to new medicines of major public health interest.
August 25, 2014
10:30 EDTYELPYelp at high of day, up 2% after GrubHub halted for pending news
August 24, 2014
21:56 EDTYELPB. Riley to hold a tour
Silicon Valley Tech Tour travels throughout Silicon Valley on August 25-27.
August 22, 2014
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
10:01 EDTCOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:05 EDTCOGCabot Oil & Gas downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Cabot Oil & Gas to Hold saying its Buy thesis hasn't played out. The firm lowered its price target for shares to $38 from $40.
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
15:54 EDTSWNEnerCom to hold a conference
Subscribe for More Information
05:27 EDTGFIGold Fields sells 51% stake in Chucapaca Project to Buenaventura for $81M
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use